Vir Biotechnology, Inc. (VIR)

Vir Biotechnology Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	174.05	254.84	861.31	356.41	444.57	115.52
Short-Term Investments	989.05	1,281	1,553	360.33	300.29	274.1
Cash & Cash Equivalents	1,163	1,536	2,415	716.74	744.85	389.62
Cash Growth	-48.56%	-36.40%	236.90%	-3.77%	91.18%	256.78%
Receivables	0	0	0	773.08	0	0
Other Current Assets	50	52.55	104.36	73	27.51	13.38
Total Current Assets	1,213	1,588	2,519	1,563	772.37	403
Property, Plant & Equipment	162.82	167.2	188.17	130.05	79.89	16.31
Long-Term Investments	366.15	111.72	30.58	208.39	6.92	31.59
Goodwill and Intangibles	39.4	39.5	49.69	50.22	50.76	52.63
Other Long-Term Assets	12.5	12.41	14.57	2.78	8.83	8.55
Total Long-Term Assets	580.87	330.83	283.01	391.45	146.4	109.08
Total Assets	1,794	1,919	2,802	1,954	918.76	512.07
Accounts Payable	7.11	6.33	6.42	6.52	5.08	5.88
Deferred Revenue	16.22	66.38	68.72	102.02	10.27	18.85
Other Current Liabilities	70.73	102.69	435.88	232.7	83.72	34.47
Total Current Liabilities	94.07	175.41	511.03	341.24	99.06	59.21
Long-Term Debt	109.17	111.67	123.84	133.56	66.56	0
Other Long-Term Liabilities	43.37	41.74	89.26	47.62	36.29	28.92
Total Long-Term Liabilities	152.55	153.42	213.1	181.18	102.85	28.92
Total Liabilities	246.61	328.82	724.13	522.42	201.91	88.13
Total Debt	109.17	111.67	123.84	133.56	66.56	0
Debt Growth	-10.12%	-9.82%	-7.28%	100.67%	-	-
Retained Earnings	-303.1	-237.82	377.24	-138.6	-667.18	-368.52
Comprehensive Income	-2.4	-0.82	-9.12	-1.1	-1.28	-0.6
Shareholders' Equity	1,547	1,590	2,078	1,432	716.85	423.94
Net Cash / Debt	1,054	1,424	2,291	583.18	678.3	389.62
Net Cash / Debt Growth	-50.74%	-37.84%	292.83%	-14.02%	74.09%	256.78%
Net Cash Per Share	7.79	10.62	16.99	4.37	5.69	12.84
Working Capital	1,119	1,413	2,008	1,222	673.3	343.79
Book Value Per Share	11.44	11.86	15.67	11.02	6.02	13.97

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).